Longitudinal bone growth, and hence stature, are functions of growth plate chondrocyte proliferation and hypertrophy. Insulin-like growth factor 1 (Igf1) is reputed to augment longitudinal bone growth by stimulating growth plate chondrocyte proliferation. In this study, however, we demonstrate that chondrocyte numbers and proliferation are normal in Igf1 null mice despite a 35% reduction in the rate of long bone growth. Igf1 null hypertrophic chondrocytes differentiate normally in terms of expressing specialized proteins such as collagen X and alkaline phosphatase, but are smaller than wildtype at all levels of the hypertrophic zone. The terminal hypertrophic chondrocytes, which form the scaffold on which long bone growth extends, are reduced in linear dimension by 30% in Igf1 null mice, accounting for most of their decreased longitudinal growth. The expression of the insulin-sensitive glucose transporter, GLUT4, is significantly decreased and the insulin-regulated enzyme glycogen synthase kinase 3␤ (GSK3) is hypo-phosphorylated in Igf1 null chondrocytes. Glycogen levels were significantly decreased and ribosomal RNA levels were reduced by almost 75% in Igf1 null chondrocytes. These data suggest that Igf1 promotes longitudinal bone growth by 'insulin-like' anabolic actions which augment chondrocyte hypertrophy.-Wang, J., Zhou, J., Bondy, C. A. Igf1 promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. FASEB J. 13, 1985-1990 (1999) 
The rate of longitudinal bone growth is approximated by the rate of production of new growth plate chondrocytes times the average size of terminal hypertrophic chondrocytes (1) (2) (3) . This process is exquisitely sensitive to regulation by growth hormone (GH), which may produce alterations of severalfold in adult stature. Insulin-like growth factor 1 (Igf1, also known as somatomedin C) is an important mediator of GH's effects on longitudinal growth, although its mode of action remains controversial. In the original 'somatomedin hypothesis', it was proposed that GH's primary effect was to stimulate Igf1 production by the liver, with Igf1 then responsible for stimulating the longitudinal expansion of growth plates in an endocrine fashion (4) . More recent work has suggested that GH may act directly at the growth plate to amplify the production of chondrocytes from germinal zone precursors and then to induce local Igf1 synthesis, which is thought to stimulate the clonal expansion of chondrocyte columns in an autocrine/paracrine manner (5) . The notion that GH induces chondrocyte Igf1 synthesis has been challenged, however, by the finding that Igf2, rather than Igf1, is synthesized by growth plate chondrocytes in vivo (6, 7) .
Despite the uncertainty about its mode of action, Igf1 clearly has an important role in longitudinal bone growth, since Igf1 gene deletion results in dwarfism in mice (8, 9) and extreme short stature in humans (10) . To elucidate Igf1's role in longitudinal bone growth, this study has compared tibial growth and analyzed tibial growth plate characteristics in Igf1 null and littermate wild-type mice.
MATERIALS AND METHODS

Mice
The Igf1 deletion mouse line used in this study was generated by Lynn Powell-Braxton at Genentech, Inc., San Francisco (9), bred for six generations into CD1 strain obtained from Taconic Farms, (Germantown, N.Y.), and maintained in our facility. The mice were used in a protocol approved by the NICHD Animal Use and Care Committee and were killed by CO 2 inhalation between 1:00 and 2:00 pm, 1 h after intraperitoneal 3 H-thymidine (2 Ci/g) or BRDU injection (10 l/g, Calbiochem HCS24). Tibias were dissected, fixed in formalin, decalcified in EDTA, embedded in paraffin, and cut longitudinally into 5 sections that were mounted onto poly-Llysine-coated slides.
Morphometry
The longitudinal dimensions of the tibia and of the proximal tibial growth plate were measured on photomicrographs of anatomically matched, midsagittal sections taken at 5 and 200ϫ. For the growth plate dimensions, three different measurements, clustered about the midline, were taken on each of two sections for each animal; the data were meaned for each animal, then pooled and meaned for each group. Terminal chondrocyte longitudinal diameter was measured using micrographs taken at 400ϫ. Measurements were made only on cells with intact superior and inferior transverse septa. The photographs were coded and masked prior to analysis so that the observer did not know to which group the samples belonged.
Histochemistry
Immunohistochemistry was performed by the avidin-biotinimmunoperoxidase method as described previously (11) . Tissue sections were deparaffinized, rehydrated, and digested in 0.5% Trypsin (Sigma, St. Louis, Mo.) at 37°C for 30 min prior to immunoreaction. A polyclonal antibody reactive against the unique carboxyl terminal domain of collagen X was a gift from Dr. Haronen (12) . The polyclonal antibodies used to detect BRDU, GLUT 4, and the serine-phosphorylated form of GSK-3␤ (9) were obtained from Chemicon (Temecula, Calif.). The monoclonal antibody detecting both active and inactive forms of GSK-3␤ was obtained from Transduction Laboratories (Lexington, Ky.). All primary antibodies were used at a dilution of 1:200. Sections were incubated with peroxidase-conjugated secondary antibody (1:200) for 30 min at room temperature. The signal was detected and amplified using the ABC peroxidase method (Vector, Burlingame, Calif.) and visualized with 3,3Ј-diaminobenzidine. Sections were counterstained with methyl green. Parallel incubations omitting the primary antibody were used to establish the level of nonspecific background staining.
Deparaffinized sections were dipped in Kodak NTB2 nuclear emulsion and exposed at 4°C for 3 wk, developed, fixed, and lightly counterstained with hematoxylin for detection of nuclear 3 H-thymidine incorporation. Positive cells had 5 or more grains/nucleus. Slides were masked and coded to conceal group designations prior to analysis.
Histological staining of glycogen was performed by the periodic acid-Schiff (PAS) reaction. Sections were first deparaffinized in xylene, rehydrated, and oxidized in 0.1% periodic acid for 5 min. After washing in water, slides were stained in 0.5% Schiff's solution (Sigma) for 15 min and counterstained with hematoxylin. For negative control, parallel sections were treated with 0.5% ␣-amylase (Sigma) at 37°C for 90 min before PAS staining. PAS 'positivity' was determined by the presence of fuchsia-colored staining.
In situ hybridization was performed as described previously (7) using 35 S-labeled antisense RNA probes synthesized from DNA fragments corresponding to nucleotides 4400 -4515 of the 28S-and nucleotides 715-794 of the 18S ribosomal RNA genes (Ambion, Austin, Tex.). After exposure to Kodak NTB2 emulsion for 3 days, hybridized slides were developed, fixed, and counterstained with hematoxylin and eosin. RNA was quantified by silver grain counting under oil at 630ϫ.
Data analysis
Data for each group (nϭ4 -8) are expressed as means with standard errors. Differences between groups were analyzed by analysis of variance using Stat View 4.1 (Abacus Systems), followed by Fisher's least significant difference tests. A P value Ͻ0.05 was taken as significant.
RESULTS
Growth plate morphometry and chondrocyte proliferation
To determine the cause of reduced long bone growth in the Igf1 null mouse, we compared chondrocyte proliferation and hypertrophy in tibial growth plates from wild-type (WT) and Igf1 null mice at postnatal day 20 (P20, Fig. 1 , Table 1 ). P20 was chosen because this is when the GH/IGF1-dependent growth spurt starts. Furthermore, the epiphysial growth plate is most active in terms of proliferation at this time (13) . The cells of the epiphysial growth plate demonstrate synchronized functional and morphological changes, which are manifested in characteristic horizontal zones. The germinal zone (GZ) Table 1 consists of a thin layer of small, undifferentiated cells immediately adjacent to epiphysial bone giving rise to proliferative chondrocytes. This zone is significantly increased in width and cell number in the Igf1 null growth plate (Fig. 1, Table 1 ). This expansion of the GZ is likely due to enhanced GH activity in the Igf1 null mouse, since circulating Igf1 normally inhibits GH secretion in a negative feedback loop.
The proliferative zone (PZ) is formed of columns of rapidly dividing chondrocytes resembling stacks of coins. The length of the PZ and the number of chondrocytes per column are equal in WT and Igf1 null mice ( Fig. 1 and Table 1 ). The proliferation rate, assessed by DNA labeling index (Table 1) , is also equal. Growth plate chondrocytes undergo terminal differentiation as hypertrophic chondrocytes, ultimately increasing in height in the direction of growth by four-to fivefold (2, 3) before they are incorporated into bone at the metaphysial end of the growth plate. The length of the Igf1 null hypertrophic zone (HZ) is reduced by ϳ35%, although the number of hypertrophic cells per column is equal to WT (Fig. 1, Table 1 ). Igf1 null chondrocytes are obviously smaller at all levels of the HZ, with the mean longitudinal diameter of terminal hypertrophic cells reduced by ϳ30% (Table 1 ). This degree of impairment in chondrocyte hypertrophy correlates with the decreased rate of longitudinal bone growth observed in Igf1 null mice. The GH-dependent postnatal growth spurt occurs between P20 -40. During this period, the WT tibia grows at a rate of ϳ290 /day (from 13.3Ϯ0.5 to 19.1Ϯ0.8 mm), whereas the Igf1 null grows ϳ185 /day (from 10.5Ϯ0.6 to 14.2Ϯ0.4 mm). This represents an ϳ35% reduction in longitudinal growth rate for the Igf1 null mouse. These data suggest that impaired chondrocyte hypertrophy is the major cause of short stature in Igf1 deficiency.
Chondrocyte hypertrophy
The differentiation of proliferative into hypertrophic chondrocytes is marked by the appearance of collagen X expression (14, 15) . Collagen X immunoreactivity is qualitatively normal, although somewhat less abundant in the Igf1 null growth plate (Fig. 2) . A similar pattern was found for the expression of alkaline phosphatase and bone sialoprotein, other 'markers' of hypertrophic differentiation (data not shown). Thus, it appears that these cells differentiate normally, but fail to attain full somatic growth. Given the marked homology between insulin and Igf1 and between their cognate receptors (16), we hypothesized that Igf1 may act in insulin-like anabolic fashion to promote chondrocyte hypertrophy. Thus, we examined the expression of well established targets of insulin's anabolic actions. Among the facilitative glucose transporters, GLUT4 expression is known to be highly dependent on insulin (17) . GLUT4 immunoreactivity was significantly reduced in Igf1 null a All data are from P20 mice. Measurements given in mm or m represent the longitudinal dimension of the structure parallel to the long axis of the bone. The cell number data for the germinal (GZ) and hypertrophic zones (HZ) represent the mean number of cells in single columns spanning the entire longitudinal diameter of the zone; the data for the proliferative zone represent number of cells in 50 in a closely packed column. The DNA labeling index (LI) was determined by scoring the number of BRDU-positive nuclei per total nuclei in PZ. Similar results were obtained in experiments using 3 H-thymidine incorporation. All data are means Ϯ sem for the right tibias from 4 mice/group. Similar data were obtained from analysis of the left tibias. A P value Ͻ 0.05 was taken as significant. hypertrophic chondrocytes, both in terms of the number of positively stained cells and in the degree of intensity demonstrated by positive cells (Fig. 3A, B, 
Table 2).
Another well-known target of insulin action is the enzyme glycogen synthase kinase 3␤ (GSK3␤). Activation of a signaling cascade proceeding through PI3K and protein kinase B/Akt results in the serine phosphorylation and inhibition of GSK3␤ activity (reviewed in ref 18 ). This in turn relieves GSK3␤-induced inhibition of glycogen synthase, thus promoting glycogen synthesis. Glycogen normally is accumulated by proliferative and early hypertrophic chondrocytes and depleted during the late stages of chondrocyte hypertrophy (19) . GSK3␤ immunoreactivity was abundant in proliferative and hypertrophic chondrocytes in both WT and Igf1 null growth plates ( Table 2 ). An antibody specific for serine-phosphorylated GSK3␤ (9), however, demonstrated greatly reduced immunostaining for the inactive form of the enzyme in Igf1 null chondrocytes (Fig. 3C , D, Table  2 ). As predicted from the reduced level of serinephosphorylated GSK3␤, PAS histochemical staining showed significantly reduced glycogen stores in the Igf1 null growth plate (Fig. 3E, F, Table 2 ).
Reduced glucose transport and intracellular glycogen stores may result in reduction of intracellular ATP supply and substrates for protein synthesis, particularly in cells dependent on glycolysis for energy production, as are hypertrophic chondrocytes (20) . Since energy and/or substrate deficit may lead to down-regulation of ribosomal RNA (rRNA) synthesis (21), we compared cellular levels of rRNA in WT and Igf1 null growth plates using in situ hybridization. This analysis showed a drastic, ϳ70% reduction in rRNA content in Igf1 null hypertrophic chondrocytes and a lesser reduction in proliferative chondrocytes (Fig. 4 and Table 3 ). It is noteworthy that rRNA is more abundant in hypertrophic than proliferative chondrocytes, consistent with observations that mitochondria, Golgi, and endoplasmic reticulum are all more abundant in hypertrophic than in proliferative chondrocytes (22) .
DISCUSSION
This study of longitudinal bone growth in the Igf1 null mouse has shown that growth plate chondrocyte proliferation and cell numbers are preserved despite an ϳ35% reduction in the rate of long bone growth. The growth defect due to Igf1 deletion is traced to an attenuation of chondrocyte hypertrophy, which is associated with reduced glucose transporter expression and glycogen synthesis and with reduced ribosomal RNA levels. These findings suggest that Igf1's mechanism of action in promoting statural growth right (B, D, F ). A, B) Immunostaining of the insulin-regulated GLUT4. Little GLUT4 is detected in Igf1 null chondrocytes although it is abundant in some bone marrow cells in these mice (B). C, D) Immunodetection of the ser9-phosphoform of GSK3b; E, F) PAS staining of glycogen deposits. involves 'insulin-like' anabolic effects, supporting the extraordinary biosynthetic activity, somatic growth, and matrix production that characterize hypertrophic chondrocytes. The present study supports the view that GH expands the pool of chondrocyte progenitors through direct effects on the growth plate germinal zone (23, 24) , since the increased cellularity of the Igf1 null germinal zone may be attributed to increased GH secretion in the absence of negative feedback from Igf1. Igf1's role in long bone growth revealed in this study, however, refutes the prevailing view that this peptide is responsible for stimulating the clonal proliferation of growth plate chondrocytes (reviewed in ref 5). We have previously questioned this hypothesis, based on the finding that Igf2 rather than Igf1 is expressed by proliferating chondrocytes (6, 7) . The present data demonstrate that Igf1's major effect on the growth plate is amplification of chondrocyte size, not proliferation. This is not to say that Igf1 normally has no role in chondrocyte proliferation, since enhanced GH action in the Igf1 null growth plate may compensate for some loss of Igf1 stimulation of chondrocyte proliferation. Also, the present data do not dispute the fact that exogenous Igf1 supplied in vivo or added to growth plate or chondrocyte cultures in vitro may enhance proliferation, since the Igf1 receptor is expressed by all types of chondrocytes (7). We would argue, however, that chondrocyte proliferation in vivo is stimulated primarily by Igf2 in an autocrine/paracrine fashion, explaining why no major deficit is seen with Igf1 deletion. In contrast, the ϳ30% reduction in linear growth of hypertrophic chondrocytes and corresponding reduction in longitudinal bone growth seen in Igf1 null mice demonstrate that augmentation of chondrocyte somatic growth is Igf1's unique and essential role in amplifying statural growth.
Terminal hypertrophic chondrocytes are the quantal units for transformation of cartilage into bone. If the number of chondrocytes coming through the system per day is equal, then the size of the terminal units determines the longitudinal bone growth rate (2, 3, 22, 25) . The present observations that the number of cells in the chondrocyte columns and chondrocyte DNA labeling indices are equal in the two groups suggest that the chondrocyte proliferation rate is equal in Igf1 null and WT mice. The differentiation of proliferative into hypertrophic chondrocytes also appears to occur normally, as evidenced by typical collagen X, bone sialoprotein and alkaline phosphatase expression in the Igf1 null growth plate. Furthermore, the fact that the proportion of cells in proliferative and hypertrophic zones is equal in both groups argues that progress in differentiation from one stage to another proceeds normally in Igf1 null growth plates. Thus, the only feature of growth plate expansion that is clearly S-labeled RNA probe complementary to the 28S ribosomal RNA shows that steady-state RNA levels are greater in hypertrophic compared with proliferative chondrocytes, and markedly greater in WT than Igf1 null chondrocytes in both zones (see Table  3 ). Bar ϭ 200 . a Sections from the proximal tibias from WT and Igf1 null mice were hybridized to a radioabeled RNA probe complementary to 28S ribosomal RNA and exposed to nuclear emulsion for three days (Fig.  4) . Exposed silver grains were counted over individual cells in the proliferative and hypertrophic zones and data are expressed as mean grains per cell (Ϯsem). disturbed in Igf1 null mice is the extent of chondrocyte hypertrophy, and the degree of attenuation of this process corresponds to the degree of reduction in longitudinal growth.
The rapid expansion of hypertrophic chondrocyte size is extraordinary, but the factors regulating this dramatic process have been unknown. The present data suggest that Igf1 enhances chondrocyte hypertrophy by insulin-like actions such as boosting glucose and amino acid uptake and utilization. Supporting this view, the Igf1 receptor, which is structurally and functionally homologous to the insulin receptor, is known to mediate such anabolic effects (16) , including regulation of GLUT4 (26) . We have shown that GLUT4 expression and GSK3␤ serine phosphorylation are significantly diminished in Igf1 null hypertrophic chondrocytes, resulting in reduced glycogen in these cells. Glycogen stores are normally accumulated by proliferative and early hypertrophic chondrocytes and depleted during maturation of the hypertrophic chondrocytes (19, 27) . Hypertrophic chondrocytes are highly active metabolically and are dependent on glycolysis to fuel their expansive biosynthetic activity (20) . The decrease in rRNA in Igf1 null hypertrophic chondrocytes may reflect cellular 'starvation' for fuel and building blocks for protein synthesis (21) . The present data suggest that Igf1 acts in a truly insulin-like manner to enhance chondrocyte glucose uptake and glycogen and protein synthesis, thus promoting maximal somatic growth and matrix production and enhancing the rate of linear bone growth by ϳ30%.
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